Incidence and duration of cumulative bisphosphonate use among community-dwelling persons with or without Alzheimer’s disease

Manuscript Number: 

15-1181R1

Author(s): 
Sirpa Hartikainen, Heidi Taipale, Antti Tanskanen, Jari Tiihonen, Miia Tiihonen

Disclosures

Sirpa Hartikainen

  • Nothing to Disclose

Heidi Taipale

  • Nothing to Disclose

Antti Tanskanen

  • Nothing to Disclose

Jari Tiihonen

  • Consulting Fees:
    Serving as a consultant to AstraZeneca, Bristol-Myers Squibb, Eli Lilly, F. Hoffman-La Roche, Janssen-Cilag, Lundbeck, and Organon. Member of advisory boards in AstraZeneca, Eli Lilly, Janssen-Cilag, and Otsuka. Received fees for giving expert opinions to AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Janssen-Cilag, Lundbeck, Otsuka, and Pfizer.
    Lecture Fees:
    Lecture fees from AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Janssen-Cilag, Lundbeck, Novartis, Otsuka, and Pfizer.
    Grants
    • Agency: 
      Stanley Foundation
      Dates: 
      2012 - 2014
    • Agency: 
      Sigrid Jusélius Foundation
      Dates: 
      2014 - 2015

Miia Tiihonen

  • Nothing to Disclose